Literature DB >> 28096543

Therapy: Experimental portal hypertension - pinning hopes on FXR agonists?

Katrina Ray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28096543     DOI： 10.1038/nrgastro.2017.6

Source DB:  PubMed          Journal:  Nat Rev Gastroenterol Hepatol        ISSN： 1759-5045            Impact factor:   46.802


× No keyword cloud information.
  1 in total

1.  The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction.

Authors:  Philipp Schwabl; Eva Hambruch; Berit A Seeland; Hubert Hayden; Michael Wagner; Lukas Garnys; Bastian Strobel; Tim-Lukas Schubert; Florian Riedl; Dieter Mitteregger; Michael Burnet; Patrick Starlinger; Georg Oberhuber; Ulrich Deuschle; Nataliya Rohr-Udilova; Bruno K Podesser; Markus Peck-Radosavljevic; Thomas Reiberger; Claus Kremoser; Michael Trauner
Journal:  J Hepatol       Date:  2016-12-18       Impact factor: 25.083
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.